{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:14:14Z","timestamp":1791252854900,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s12325-016-0324-7","type":"journal-article","created":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T05:49:45Z","timestamp":1459576185000},"page":"699-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":151,"title":["Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"33","author":[{"given":"Joseph Ralph","family":"Kallini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Gabr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,2]]},"reference":[{"issue":"2","key":"324_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"324_CR2","volume-title":"Harrison\u2019s principles of internal medicine, 19e","author":"BI Carr","year":"2015","unstructured":"Carr BI. Tumors of the liver and biliary tree. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, editors. Harrison\u2019s principles of internal medicine, 19e. New York: McGraw-Hill; 2015."},{"issue":"4","key":"324_CR3","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"European Association for the Study of the Liver","year":"2012","unstructured":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908\u201343.","journal-title":"J Hepatol"},{"issue":"9319","key":"324_CR4","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734\u20139.","journal-title":"Lancet"},{"issue":"5","key":"324_CR5","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164\u201371.","journal-title":"Hepatology"},{"key":"324_CR6","doi-asserted-by":"crossref","unstructured":"Kallini JR, Miller FH, Gabr A, Salem R, Lewandowski RJ. Hepatic imaging following intra-arterial embolotherapy. Abdom Radiol (NY). 2016. doi: 10.1007\/s00261-016-0639-5 .","DOI":"10.1007\/s00261-016-0639-5"},{"issue":"4","key":"324_CR7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/s-0034-1394142","volume":"34","author":"B Sangro","year":"2014","unstructured":"Sangro B, Salem R. Transarterial chemoembolization and radioembolization. Semin Liver Dis. 2014;34(4):435\u201343.","journal-title":"Semin Liver Dis"},{"key":"324_CR8","unstructured":"National Comprehensive Cancer Network. Hepatobiliary Cancers (Version 1.2016). http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf . Accessed 20 Mar 2016."},{"issue":"20","key":"324_CR9","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.4254\/wjh.v7.i20.2274","volume":"7","author":"D Galun","year":"2015","unstructured":"Galun D, Basaric D, Zuvela M, et al. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol. 2015;7(20):2274\u201391. doi: 10.4254\/wjh.v7.i20.2274 .","journal-title":"World J Hepatol"},{"issue":"1","key":"324_CR10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1055\/s-2006-939842","volume":"23","author":"RJ Lewandowski","year":"2006","unstructured":"Lewandowski RJ, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol. 2006;23(1):64\u201372.","journal-title":"Semin Intervent Radiol"},{"issue":"5","key":"324_CR11","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2013.12.040","volume":"88","author":"R Hickey","year":"2014","unstructured":"Hickey R, Mulcahy MF, Lewandowski RJ, et al. Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. Int J Radiat Oncol Biol Phys. 2014;88(5):1025\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"324_CR12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijrobp.2006.11.060","volume":"68","author":"A Kennedy","year":"2007","unstructured":"Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68(1):13\u201323.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2 Suppl 1","key":"324_CR13","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1002\/lt.20036","volume":"10","author":"BI Carr","year":"2004","unstructured":"Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transplant. 2004;10(2 Suppl 1):S107\u201310.","journal-title":"Liver Transplant"},{"issue":"10","key":"324_CR14","first-page":"1673","volume":"41","author":"JE Dancey","year":"2000","unstructured":"Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41(10):1673\u201381.","journal-title":"J Nucl Med"},{"issue":"5 Suppl 1","key":"324_CR15","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1053\/j.gastro.2004.09.034","volume":"127","author":"JF Geschwind","year":"2004","unstructured":"Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S194\u2013205.","journal-title":"Gastroenterology"},{"issue":"1","key":"324_CR16","first-page":"49","volume":"3","author":"J Goin","year":"2004","unstructured":"Goin J, Roberts C, Dancey J, Sickles C, Leung D, Soulen M. Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter arterial chemo-embolization versus yttrium-90 glass microspheres. World J Nucl Med. 2004;3(1):49\u201356.","journal-title":"World J Nucl Med"},{"issue":"7","key":"324_CR17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/jso.20609","volume":"94","author":"LM Kulik","year":"2006","unstructured":"Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol. 2006;94(7):572\u201386.","journal-title":"J Surg Oncol"},{"issue":"3","key":"324_CR18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0360-3016(97)00818-3","volume":"40","author":"WY Lau","year":"1998","unstructured":"Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40(3):583\u201392.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"324_CR19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","volume":"138","author":"R Salem","year":"2010","unstructured":"Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52\u201364.","journal-title":"Gastroenterology"},{"issue":"3","key":"324_CR20","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","volume":"54","author":"B Sangro","year":"2011","unstructured":"Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868\u201378.","journal-title":"Hepatology"},{"issue":"2","key":"324_CR21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jvir.2013.11.005","volume":"25","author":"VL Gates","year":"2014","unstructured":"Gates VL, Marshall KG, Salzig K, Williams M, Lewandowski RJ, Salem R. Outpatient single-session yttrium-90 glass microsphere radioembolization. J Vasc Intervent Radiol. 2014;25(2):266\u201370.","journal-title":"J Vasc Intervent Radiol"},{"key":"324_CR22","unstructured":"TheraSphere Yttrium-90 microspheres package insert. Kanata CMN. http:\/\/www.therasphere.com\/physicians-package-insert\/TS_PackageInsert_USA_v12.pdf ."},{"key":"324_CR23","unstructured":"SIRS-Spheres Yttrium-90 microspheres package insert. Singapore Science Park SSM. http:\/\/www.sirtex.com\/media\/29845\/ssl-us-10.pdf ."},{"issue":"4","key":"324_CR24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/hpb.12135","volume":"16","author":"PM Piana","year":"2014","unstructured":"Piana PM, Bar V, Doyle L, et al. Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. HPB (Oxford). 2014;16(4):336\u201341.","journal-title":"HPB (Oxford)"},{"issue":"7","key":"324_CR25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/01.RVI.0000164324.79242.B2","volume":"16","author":"DM Liu","year":"2005","unstructured":"Liu DM, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Intervent Radiol. 2005;16(7):911\u201335.","journal-title":"J Vasc Intervent Radiol"},{"issue":"11","key":"324_CR26","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jvir.2013.07.011","volume":"24","author":"N Hamoui","year":"2013","unstructured":"Hamoui N, Minocha J, Memon K, et al. Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres. J Vasc Intervent Radiol. 2013;24(11):1743\u20135.","journal-title":"J Vasc Intervent Radiol"},{"issue":"5","key":"324_CR27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/COC.0b013e318168ef65","volume":"31","author":"R Salem","year":"2008","unstructured":"Salem R, Parikh P, Atassi B, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31(5):431\u20138.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"324_CR28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jvir.2014.09.013","volume":"26","author":"FE Boas","year":"2015","unstructured":"Boas FE, Do B, Louie JD, et al. Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma. J Vasc Intervent Radiol. 2015;26(1):69\u201373.","journal-title":"J Vasc Intervent Radiol"},{"issue":"3","key":"324_CR29","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2214\/AJR.06.0707","volume":"188","author":"FH Miller","year":"2007","unstructured":"Miller FH, Keppke AL, Reddy D, et al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol. 2007;188(3):776\u201383.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"324_CR30","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.23944","volume":"52","author":"P Hilgard","year":"2010","unstructured":"Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741\u20139.","journal-title":"Hepatology."},{"issue":"3","key":"324_CR31","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","volume":"54","author":"B Sangro","year":"2011","unstructured":"Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868\u201378.","journal-title":"Hepatology"},{"issue":"5","key":"324_CR32","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.26014","volume":"57","author":"V Mazzaferro","year":"2013","unstructured":"Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57(5):1826\u201337.","journal-title":"Hepatology."},{"issue":"2","key":"324_CR33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","volume":"140","author":"R Salem","year":"2011","unstructured":"Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497\u2013507.e2.","journal-title":"Gastroenterology"},{"key":"324_CR34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1745-6215-13-144","volume":"13","author":"BA Seinstra","year":"2012","unstructured":"Seinstra BA, Defreyne L, Lambert B, et al. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials. 2012;13:144.","journal-title":"Trials."},{"key":"324_CR35","doi-asserted-by":"crossref","unstructured":"Soydal C, Arslan MF, Kucuk ON, Idilman R, Bilgic S. Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients. Nucl Med Commun. 2016 (in press).","DOI":"10.1097\/MNM.0000000000000486"},{"issue":"5","key":"324_CR36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5582\/bst.2015.01089","volume":"9","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Li Y, Ji H, Zhao X, Lu H. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a meta-analysis. Biosci Trends. 2015;9(5):289\u201398.","journal-title":"Biosci Trends"},{"issue":"1","key":"324_CR37","first-page":"239","volume":"36","author":"O Akinwande","year":"2016","unstructured":"Akinwande O, Philips P, Scoggins C, Martin RC. Radioembolization versus chemoembolization (DEBDOX) for the treatment of unresectable hepatocellular carcinoma: a propensity matched study. Anticancer Res. 2016;36(1):239\u201346.","journal-title":"Anticancer Res"},{"issue":"8","key":"324_CR38","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/j.1600-6143.2009.02695.x","volume":"9","author":"RJ Lewandowski","year":"2009","unstructured":"Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9(8):1920\u20138.","journal-title":"Am J Transplant"},{"issue":"2","key":"324_CR39","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/liv.12637","volume":"35","author":"A Fouly El","year":"2015","unstructured":"El Fouly A, Ertle J, El Dorry A, et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int. 2015;35(2):627\u201335.","journal-title":"Liver Int"},{"issue":"4","key":"324_CR40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/cer.13.37","volume":"2","author":"M Xing","year":"2013","unstructured":"Xing M, Kokabi N, Camacho JC, Kooby DA, El-Rayes BF, Kim HS. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. J Comp Eff Res. 2013;2(4):435\u201344.","journal-title":"J Comp Eff Res"},{"issue":"3","key":"324_CR41","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00270-012-0481-2","volume":"36","author":"LE Moreno-Luna","year":"2013","unstructured":"Moreno-Luna LE, Yang JD, Sanchez W, et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013;36(3):714\u201323.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"12","key":"324_CR42","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.jvir.2011.08.013","volume":"22","author":"C Lance","year":"2011","unstructured":"Lance C, McLennan G, Obuchowski N, et al. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Intervent Radiol. 2011;22(12):1697\u2013705.","journal-title":"J Vasc Intervent Radiol"},{"issue":"2","key":"324_CR43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jvir.2009.10.013","volume":"21","author":"DA Kooby","year":"2010","unstructured":"Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Intervent Radiol. 2010;21(2):224\u201330.","journal-title":"J Vasc Intervent Radiol"},{"key":"324_CR44","doi-asserted-by":"crossref","unstructured":"Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013;11(10):1358\u201365.e1.","DOI":"10.1016\/j.cgh.2013.04.028"},{"issue":"6","key":"324_CR45","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/liv.12750","volume":"35","author":"FT Kolligs","year":"2015","unstructured":"Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. 2015;35(6):1715\u201321.","journal-title":"Liver Int"},{"issue":"3","key":"324_CR46","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/liv.12574","volume":"35","author":"A Gramenzi","year":"2015","unstructured":"Gramenzi A, Golfieri R, Mosconi C, et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 2015;35(3):1036\u201347.","journal-title":"Liver Int"},{"issue":"5","key":"324_CR47","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s00270-011-0292-x","volume":"35","author":"SM Ibrahim","year":"2012","unstructured":"Ibrahim SM, Kulik L, Baker T, et al. Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2012;35(5):1094\u2013101.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"324_CR48","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"8","key":"324_CR49","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jvir.2010.04.012","volume":"21","author":"M Inarrairaegui","year":"2010","unstructured":"Inarrairaegui M, Thurston KG, Bilbao JI, et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Intervent Radiol. 2010;21(8):1205\u201312.","journal-title":"J Vasc Intervent Radiol."},{"issue":"4","key":"324_CR50","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00259-015-3210-7","volume":"43","author":"J Edeline","year":"2016","unstructured":"Edeline J, Crouzet L, Campillo-Gimenez B, et al. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging. 2016;43(4):635\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"324_CR51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhep.2014.03.023","volume":"61","author":"L Kulik","year":"2014","unstructured":"Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90\u00a0\u00b1\u00a0sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014;61(2):309\u201317.","journal-title":"J Hepatol"},{"issue":"7","key":"324_CR52","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jvir.2014.04.014","volume":"25","author":"N Rostambeigi","year":"2014","unstructured":"Rostambeigi N, Dekarske AS, Austin EE, Golzarian J, Cressman EN. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Vasc Intervent Radiol. 2014;25(7):1075\u201384.","journal-title":"J Vasc Intervent Radiol"},{"issue":"3","key":"324_CR53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jvir.2011.11.016","volume":"23","author":"CE Ray Jr","year":"2012","unstructured":"Ray CE Jr, Battaglia C, Libby AM, Prochazka A, Xu S, Funaki B. Interventional radiologic treatment of hepatocellular carcinoma-a cost analysis from the payer perspective. J Vasc Intervent Radiol. 2012;23(3):306\u201314.","journal-title":"J Vasc Intervent Radiol"},{"issue":"1","key":"324_CR54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijrobp.2009.10.062","volume":"79","author":"A Riaz","year":"2011","unstructured":"Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79(1):163\u201371.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"324_CR55","doi-asserted-by":"crossref","unstructured":"Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192\u2013201.","DOI":"10.1002\/hep.27057"},{"issue":"7","key":"324_CR56","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jvir.2014.03.030","volume":"25","author":"SA Padia","year":"2014","unstructured":"Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Intervent Radiol. 2014;25(7):1067\u201373.","journal-title":"J Vasc Intervent Radiol"},{"issue":"4","key":"324_CR57","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/SLA.0b013e3181b674df","volume":"250","author":"Y Kishi","year":"2009","unstructured":"Kishi Y, Abdalla EK, Chun YS, et al. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg. 2009;250(4):540\u20138.","journal-title":"Ann Surg"},{"issue":"2","key":"324_CR58","first-page":"208","volume":"237","author":"O Farges","year":"2003","unstructured":"Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237(2):208\u201317.","journal-title":"Ann Surg"},{"issue":"1","key":"324_CR59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00270-012-0440-y","volume":"36","author":"KP Lienden van","year":"2013","unstructured":"van Lienden KP, van den Esschert JW, de Graaf W, et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol. 2013;36(1):25\u201334.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"324_CR60","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1245\/s10434-008-0222-6","volume":"16","author":"W Graaf de","year":"2009","unstructured":"de Graaf W, van den Esschert JW, van Lienden KP, van Gulik TM. Induction of tumor growth after preoperative portal vein embolization: is it a real problem? Ann Surg Oncol. 2009;16(2):423\u201330.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"324_CR61","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1245\/s10434-009-0454-0","volume":"16","author":"RC Gaba","year":"2009","unstructured":"Gaba RC, Lewandowski RJ, Kulik LM, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16(6):1587\u201396.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"324_CR62","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1245\/s10434-013-2906-9","volume":"20","author":"J Edeline","year":"2013","unstructured":"Edeline J, Lenoir L, Boudjema K, et al. Volumetric changes after (90)Y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol. 2013;20(8):2518\u201325.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"324_CR63","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00259-012-2253-2","volume":"40","author":"H Ahmadzadehfar","year":"2013","unstructured":"Ahmadzadehfar H, Meyer C, Ezziddin S, et al. Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study. Eur J Nucl Med Mol Imaging. 2013;40(1):80\u201390.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"324_CR64","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jhep.2013.06.015","volume":"59","author":"M Vouche","year":"2013","unstructured":"Vouche M, Lewandowski RJ, Atassi R, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59(5):1029\u201336.","journal-title":"J Hepatol"},{"issue":"5","key":"324_CR65","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1245\/s10434-008-0269-4","volume":"16","author":"V Pamecha","year":"2009","unstructured":"Pamecha V, Glantzounis G, Davies N, Fusai G, Sharma D, Davidson B. Long-term survival and disease recurrence following portal vein embolisation prior to major hepatectomy for colorectal metastases. Ann Surg Oncol. 2009;16(5):1202\u20137.","journal-title":"Ann Surg Oncol"},{"key":"324_CR66","doi-asserted-by":"crossref","unstructured":"Garlipp B, de Baere T, Damm R, et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology. 2014;59(5):1864\u201373.","DOI":"10.1002\/hep.26947"},{"issue":"7","key":"324_CR67","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00259-013-2395-x","volume":"40","author":"E Garin","year":"2013","unstructured":"Garin E, Lenoir L, Edeline J, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"324_CR68","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2967\/jnumed.110.080986","volume":"52","author":"VL Gates","year":"2011","unstructured":"Gates VL, Esmail AA, Marshall K, Spies S, Salem R. Internal pair production of 90Y permits hepatic localization of microspheres using routine PET: proof of concept. J Nucl Med. 2011;52(1):72\u20136.","journal-title":"J Nucl Med"},{"key":"324_CR69","doi-asserted-by":"crossref","unstructured":"Fowler KJ, Maughan NM, Laforest R, et al. PET\/MRI of hepatic 90Y microsphere deposition determines individual tumor response. Cardiovasc Intervent Radiol. 2015. doi: 10.1007\/s00270-015-1285-y .","DOI":"10.1007\/s00270-015-1285-y"},{"key":"324_CR70","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fonc.2014.00255","volume":"4","author":"SM Srinivas","year":"2014","unstructured":"Srinivas SM, Natarajan N, Kuroiwa J, et al. Determination of radiation absorbed dose to primary liver tumors and normal liver tissue using post-radioembolization (90)Y PET. Front Oncol. 2014;4:255.","journal-title":"Front Oncol"},{"issue":"11","key":"324_CR71","doi-asserted-by":"crossref","first-page":"e110401","DOI":"10.1371\/journal.pone.0110401","volume":"9","author":"AA Attarwala","year":"2014","unstructured":"Attarwala AA, Molina-Duran F, Busing KA, et al. Quantitative and qualitative assessment of yttrium-90 PET\/CT imaging. PLoS One. 2014;9(11):e110401.","journal-title":"PLoS One"},{"issue":"2","key":"324_CR72","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/liv.12622","volume":"35","author":"J Ricke","year":"2015","unstructured":"Ricke J, Bulla K, Kolligs F, et al. Safety and toxicity of radioembolization plus sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. Liver Int. 2015;35(2):620\u20136.","journal-title":"Liver Int"},{"key":"324_CR73","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/1745-6215-15-474","volume":"15","author":"V Vilgrain","year":"2014","unstructured":"Vilgrain V, Abdel-Rehim M, Sibert A, et al. Radioembolisation with yttrium90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials. 2014;15:474.","journal-title":"Trials"},{"key":"324_CR74","unstructured":"Clinicaltrials.gov. Study to compare selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma (HCC) (SIRveNIB). Updated 26 Nov 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01135056?term=01135056&rank=1 . Accessed cited 17 Mar 2016."},{"key":"324_CR75","unstructured":"Clinical Trials With TheraSphere\u00ae YTTRIUM-90 GLASS MICROSPHERES. 2016. http:\/\/www.therasphere.com\/clinicaltrials_us\/index.asp ."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0324-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T23:03:29Z","timestamp":1655420609000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0324-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,2]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["324"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0324-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,2]]}}}